Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia

Clinical Cancer Research

Volumn 21, Issue 2, 2015, Pages 329-334

  Tanfous, Mohsen Ben ^a   Sharif Askari, Bahram ^a   Ceppi, Francesco ^a   Laaribi, Haithem ^a   Gagne, Vincent ^a   Rousseau, Julie ^a   Labuda, Malgorzata ^a   Silverman, Lewis B ^d,f   Sallan, Stephen E ^d,f   Neuberg, Donna ^e   Kutok, Jeffery L ^g   Sinnett, Daniel ^a,b   Laverdiére, Caroline ^a,b   Krajinovic, Maja ^a,b,c  

^a UNIVERSITY OF MONTREAL   (Canada)

^b Departments of Pediatrics   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Pediatric Oncology   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININOSUCCINATE SYNTHASE; ARGINOSUCCINATE SYNTHASE 1; ASPARAGINASE; ASPARTATE AMMONIA LIGASE; RECOMBINANT ASPARAGINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGY; ARTICLE; ASNS GENE; ASPARAGINE SYNTHETASE GENE; ASS1 GENE; ATF5 GENE; CANCER PROGNOSIS; CHILD; CHILDHOOD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; EVENT FREE SURVIVAL; FEMALE; GENE; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HUMAN; IC50; IN VITRO STUDY; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROTECTION; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS; ENZYMOLOGY; GENE FREQUENCY; GENETIC ASSOCIATION STUDY; GENETICS; NUCLEOTIDE REPEAT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; ASPARTATE-AMMONIA LIGASE; CELL LINE, TUMOR; CHILD; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REPETITIVE SEQUENCES, NUCLEIC ACID;

EID: 84920974106     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0508     Document Type: Article

References (27)

1. Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000;14:2247-56.
2. Horowitz B, Madras BK, Meister A, Old LJ, Boyes EA, Stockert E. Asparagine synthetase activity of mouse leukemias. Science 1968;160:533-5.
3. Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:7161-7.
4. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for childrenwith acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-8.
5. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109: 896-904.
6. Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010;24:320-34.
7. Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002;99:2734-9.
8. Verma N, Kumar K, Kaur G, Anand S. L-asparaginase: a promising chemotherapeutic agent. Crit Rev Biotechnol 2007;27:45-62.
9. Kearney SL, Dahlberg SE, Levy DE, Voss SD, Sallan SE, Silverman LB. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer 2009;53:162-7.
10. Rousseau J, Gagne V, Labuda M, Beaubois C, Sinnett D, Laverdiere C, et al. ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood 2011;118: 5883-90.
11. Stams WA, den Boer ML, Holleman A, Appel IM, Beverloo HB, van Wering ER, et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 2005;105:4223-5.
12. Estes DA, Lovato DM, Khawaja HM, Winter SS, Larson RS. Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples. Br J Haematol 2007;139:20-30.
13. Fine BM, Kaspers GJ, Ho M, Loonen AH, Boxer LM. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res 2005;65:291-9.
14. Akagi T, Yin D, Kawamata N, Bartram CR, Hofmann WK, Song JH, et al. Functional analysis of a novel DNA polymorphism of a tandem repeated sequence in the asparagine synthetase gene in acute lymphoblastic leukemia cells. Leukemia Res 2009;33:991-6.
15. Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study-Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 2013;31:1202-10.
16. Chen SH, Pei D, Yang W, Cheng C, Jeha S, Cox NJ, et al. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther 2010;88:191-6.
17. Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 2011;152:452-9.
18. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
19. Buchanan CC, Torstenson ES, Bush WS, Ritchie MD. A comparison of cataloged variation between International HapMap Consortium and 1000 Genomes Project data. J Am Med Inform Assoc 2012;19: 289-94.
20. Aslanian AM, Fletcher BS, Kilberg MS. Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J 2001;357:321-8.
21. Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007;117:1049-57.
22. Pastorczak A, Fendler W, Zalewska-Szewczyk B, Gorniak P, Lejman M, Trelinska J, et al. Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment. Leukemia Res 2014;38: 180-3.
23. Krejci O, Starkova J, Otova B, Madzo J, Kalinova M, Hrusak O, et al. Upregulation of asparagine synthetase fails to avert cell cycle arrest induced by L-asparaginase in TEL/AML1-positive leukaemic cells. Leukemia 2004;18:434-41.
24. Chen SH, Yang W, Fan Y, Stocco G, Crews KR, Yang JJ, et al. A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia 2011;25:66-74.
25. Cui H, Darmanin S, Natsuisaka M, Kondo T, Asaka M, Shindoh M, et al. Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. Cancer Res 2007;67:3345-55.
26. Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, et al. Asparagine synthetase as a causal, predictive biomarker for Lasparaginase activity in ovarian cancer cells. Mol Cancer Ther 2006;5: 2613-23.
27. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, et al. Integrative molecular profiling reveals asparagine synthetase is a target in castrationresistant prostate cancer. Am J Pathol 2012;180:895-903.